Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib PK and Safety in Chinese Patients
NCT02430311Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib in solid tumor (advanced stage) (2 arms), sponsored by AstraZeneca. Primary endpoints: Single Dose PK Parameter--Cmax at Day 3, Single Dose PK Parameter--AUC at Day 3 and 11 more. Started Jun 2015; status: completed.
02
Drugs
olaparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02430311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02430311.